On the other hand, as already shown, alterations in non-BRCA1/2 HRR genes may confer sensitivity not only to PARP inhibitors but also to the WEE1 checkpoint inhibitor or the ataxia telangiectasia and Rad3-related protein inhibitor. The gene discussed is BRCA1; the disease is telangiectasis.